Guggenheim made no change to the firm’s Buy rating or $64 price target on Ionis Pharmaceuticals in a preview of the Eplontersen ATTR-PN update at AAN. The firm expects week 66 data will repeat sustained mean TTR reduction supported by a consistent safety profile, and barring any negative surprises, the talk should be about CARDIO-TTRansform Phase 3, where efficacy in the context of background tafamidis represents a major advantage relative to HELIOS-B, the analyst tells investors in a research note. The firm anticipates no liver or renal issues at the 45mg dose.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis Pharmaceuticals’ IONIS-MAPTRx shows tau reduction efficacy in Alzheimer’s
- Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints
- Ionis says FDA advisors vote in favor of potential tofersen accelerated approval
- Ionis Pharmaceuticals initiated with an Underperform at Bernstein
- Ionis Pharmaceuticals: FDA accepts NDA for eplontersen
